




BizInt Smart Charts

for Patents 3.5



- Patent databases: STN, PatBase, MicroPatent, Questel (Orbit.com, Qweb), Delphion, IDdb, Integrity, Thomson Pharma IP, TotalPatent, Thomson Innovation, Cortellis
- Non-patent literature databases: Embase, Biosis, Medline, Chemical Abstracts, etc.

_	Combined: Mousetraps (T		Patent Family							
	Title	Database	Patent Kind Date		International Patent Class	Priority Date	Patent Assignee	Inventor(s)		
29	Mousetrap	PalBase	GB 200325446 AU 2004292376 WO 05051079 EP 1691603 KR 2005110287 BR 200416076 US 2007017149	A0 AA A1 A1 A A	2003-12-03 2005-06-09 2005-08-09 2006-08-23 2006-10-24 2007-01-02 2007-01-25	A011823/02 A011823/00 A011823/00 A01823/00 A01823/00	2003-10-31	RECATT BENCKISER AU PTY LTD RECATT BENCKISER UK LTD RECORDERS BRENDYN MURRAY WATSON DUNCAN MCLEOD WEST JEFFREY	RODGERS BRENDYN M RODGERS BRENDYN MURRAY WATSON DUNCAN MC LEOD WATSON DUNCAN MC LEOD WATSON DUNCAN MCLEO WEST JEFFREY	Source prese mous enclos base, each open aligne trigge lever: mean top an ICON
10	Mousetrap	TotalPatent	US 20070017149 AJ 2004292376 BR PI04160762 BR PI0416076 BP 1691603 GB 0325446 GR 0325446 KR 1020060110287 KR 20060110287 US 2009028332 US 7506471 VO 2005051079 ZA 200603453	A1 A1 A1 A1 D0 D0 A A A1 B2 A1 A	2007-01-25	A01792916 A01792916 A01792916 A01792919	2003-10-31	Recidit Bencisser (Australia) Pty Limited	Brendyn Murray Rodgers Duncan McLeod Watson Jeffrey West	The pi a mou enclos base: each o where open; alignn trigger lever a mean top an arrang
31	MOUSETRAP	TotalPatent	WO 2005051079 AU 2004292376 BR PI04160762 BR PI0416076 BP 1691603 GB 0325446 GB 325446 KR 1020060110287 KR 20050110287 KR 20050110287 US 20070071749 US 20070071749 US 2007003453	A1 A1 A1 A1 D0 D0 A A A1 A1 B2 A	2005-08-09	A0112216 A0112218 A0112218 A0112330	2003-10-31	RECKITT BENCKISER (Australia) Py Limited RECKITT BENCKISER (UK) LIMITED	RODCERS, Brendyn, Murray WATSON, Duncan, McLeod WEST, Jeffrey	The programment of the programme





BizInt Smart Charts for Patents 3.5



GenomeQuest: GQPAT, GeneSeq

■ STN: USGENE, DGENE, PCTGEN




	Title	Patent Assignee	Seq. ID Number	Organism Species		Alignment	Percei
1	Nucleic acid sequences relating to Bacteroides fragilis for diagnostics and therapeutics	OSCIENT PHARMACEUTICALS CORPORATION WALTHAM, MA	US7090973-6862	Bacteroides fragilis		1 KVSNR-LY 7 40 KVDMSNRILY 349	70.00
2	Expression of microbial proteins in plants for production of plants with improved properties	MONSANTO TECHNOLOGY, LLC ST. LOUIS, MO	US7314974-14121	Pseudomonas fluorescens	Q: S: 5	1 K-VSMRLY 7 	70.00
3	Production and use of novel peptide-based agents for use with bi-specific antibodies	IMMUNOMEDICS INC. MORRIS PLAINS, NJ	US6962702-0008	Artificial Sequence	Q: S:	1 RSSQSIVHSNGNTYLQ 16 	93.75
4	Chimeric, human and humanized anti-CSAP monoclonal antibodies	IMMUNIMEDICS, INC. MORRIS PLAINS, NJ	US7387772-0032	Murine sp.	Q: S:	1 RSSQSIVHSNGNTYLQ 16 	93.75
5	Chimeric, human and humanized anti-CSAp monoclonal antibodies	IMMUNOMEDICS, INC. MORRIS PLAINS, NJ	US7414121-0032	Murine sp.	Q: S:	1 RSSQSIVHSNGNTYLQ 16 24 RSSQSIVHSNGNTYLE 39	93.75
6	Production and use of novel peptide-based agents for use with bi-specific antibodies	IMMUNOMEDICS, INC. MORRIS PLAINS, NJ	US7429381-0008	Artificial Sequence	Q: s:	1 RSSQSIVHSNGNTYLQ 16 + 24 RSSQSIVHSNGNTYLE 39	93.75
7	Production and use of novel peptide-based agents for use with bi-specific antibodies	IMMUNOMEDICS INC. MORRIS PLAINS, NJ	US6962702-0012	Artificial Sequence	Q: S:	1 RSSQSIVHSNGNTYLQ 16 24 RSSQSIVHSNGNTYLE 39	93.75
8	Production and use of novel peptide-based agents for use with bi-specific antibodies	IMMUNOMEDICS, INC. MORRIS PLAINS, NJ	US7429381-0012	Artificial Sequence	Q: S:	1 RSSQSIVHSNGNTYLQ 16 24 RSSQSIVHSNGNTYLE 39	93.75
9	Covalently reactive transition state analogs and methods of use thereof	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM AUSTIN. TX	US6855804-0042	Mus musculus domesticus	Q: S:	1 RSSQSIVHSNGNTYLQ 16 	93.75
	Covalently reactive transition		US7524663-0042	Mus musculus	Q:	1 RSSQSIVHSNGNTYLQ 16	93.75


_	PAT Proteins: Antibodies_Genome							
	Title	Patent Assignee	Organism Species			Alignment		Perce
1	Nucleic acid sequences relating to Bacteroides fragilis	OSCIENT PHARMACEUTICALS	Bacteroides fragilis	Q: S:	_	KVSNR-LY 7 KVDMSNRILY 349		70.00
	for diagnostics and therapeutics	CORPORATION VALTHAM, MA	Pseudomonas fluorescens	Q:	1	K-VSNRLY 7		70.00
2	Expression of microbial proteins in plants for	MONSANTO TECHNOLOGY, LLC	Artificial Sequence	S: 0:		KLVSDLNRLY 606 RSSOSIVHSNGNTYLO	16	93.75
3	production of plants with improved properties	ST. LOUIS, MO	Artiliciai Sequence	g: s:	_	RSSQSIVHSNGNTYLE	39	93.75
	Production and use of novel peptide-based agents for use with bi-specific antibodies	IMM INOMEDICS INC. MORRIS PLAINS, NJ	Murine sp.	Q: S:		RSSQSIVHSNGNTYLQ RSSQSIVHSNGNTYLE	16 39	93.75
	Chimeric, human and	IMMUNIMEDICS, INC.	Murine sp.	Q: s:		RSSQSIVHSNGNTYLQ RSSQSIVHSNGNTYLE	16 39	93.75
	Bibliographic	IMMUNUMEDICS, INC.	Artificial Sequence	Q: S:		RSSQSIVHSNGNTYLQ RSSQSIVHSNGNTYLE	16 39	93.75
	humanized anti-CSAp monoclonal antibodies	MORRIS PLAINS, NJ	Artificial Sequence	Q: S:		RSSQSIVHSNGNTYLQ	16 39	93.75
	Production and use of novel peptide-based agents for use with bi-specific antibodies	IMMUNOMEDICS, INC. MORRIS PLAINS, NJ	Artificial Sequence	Q: S:		RSSQSIVHSNGNTYLQ		93.75
	Production and use of novel	IMMUNOMEDICS INC.	Mus musculus domesticus	Q:		RSSQSIVHSNGNTYLQ		93.7
1	peptide-based agents for use with bi-specific antibodies	MORRIS PLAINS, NJ	Mus musculus	S: 0:		RSSQSIVHSNGNTYLE RSSOSIVHSNGNTYLO	****	93.7

	PAT Proteins: Antibodies_	_GenomeQuest				
	Title	Patent Assignee	Seq. ID Number	Organism Species	Alignment	Percei
1	Nucleic acid sequences relating to Bacteroides fragilis for diagnostics and therapeutics	OSCIENT " PHARMACEUTICAL! CORPORATION WALTHAM, MA	110700070 0000	Bacteroides fragilis	1 KVSNR-LY 7 340 KVDMSNRILY 349	70.00
2	Expression of microbial proteins in plants for production of plants with improved properties	MONSANTO TECHNOLOGY, LLC ST. LOUIS, MO	US7314974-14121	Pseudomonas	1 K-VSNRLY 7 597 KLVSDLNRLY 606	70.00
3	Production and use of novel peptide-based agents for use with bi-specific antibodies	IMMUNOMEDICS IN MORRIS PLAINS, N.		fluorescens	1 RSSQSIVHSNGNTYLQ 16 + 24 RSSQSIVHSNGNTYLE 39	93.75
4	Chimeric, human and humanized anti-CSAP monoclonal antibodies	IMMUNIMEDICS, INC MORRIS PLAINS, N.	US6962702-0008	Artificial Sequence	1 RSSQSIVHSNGNTYLQ 16 + 24 RSSQSIVHSNGNTYLE 39	93.75
5	Chimeric, human and humanized anti-CSAp monoclonal antibodies	IMMUNOMEDICS, IN MORRIS PLAINS, N.	Soguence I	Murine en	1 RSSQSIVHSNGNTYLQ 16 + 24 RSSQSIVHSNGNTYLE 39	93.75
6	Production and use of novel peptide-based agents for use with bi-specific antibodies	IMMUNOMEDI MORRIS PLAI	Sequence I	Murine sp.	1 RSSQSIVHSNGNTYLQ 16 + 24 RSSQSIVHSNGNTYLE 39	93.75
7	Production and use of novel peptide-based agents for use with bi-specific antibodies	IMMUNOMEDICS IN MORRIS PLAINS, N.			1 RSSQSIVHSNGNTYLQ 16 + 24 RSSQSIVHSNGNTYLE 39	93.75
8	Production and use of novel peptide-based agents for use with bi-specific antibodies	IMMUNOMEDICS, IN MORRIS PLAINS, N.	US7429381-0008	Artificial Sequence	1 RSSQSIVHSNGNTYLQ 16 + 24 RSSQSIVHSNGNTYLE 39	93.75
9	Covalently reactive transition state analogs and methods of use thereof	BOARD OF REGENT THE UNIVERSITY OF TEXAS SYSTEM	US6962702-0012	Artificial Sequence	1 RSSQSIVHSNGNTYLQ 16 + 24 RSSQSIVHSNGNTYLE 39	93.75
	Covalently reactive transition	AUSTIN, TX ADLER; BENJAMIN			1 RSSOSIVHSNGNTYLO 16	93.75


		_GenomeQuest						
	Title	Patent Assignee	Seq. ID Num			Alignment		Percentag
1	Nucleic acid sequences relating to Bacteroides fragilis for diagnostics and therapeutics	OSCIENT PHARMACEUTICALS CORPORATION WALTHAM, MA	US7090973-6	Q: s:	1 340	KVSNR-LY 7		70.00
2	Expression of microbial proteins in plants for production of plants with improved properties	MONSANTO TECHNOLOGY, LLC ST. LOUIS, MO	US7314974-1	Q:	1	K-VSNRLY 7		70.00
	Production and use of novel peptide-based agents for use with bi-specific antibodies	IMMUNOMEDICS INC. MORRIS PLAINS, NJ	US6962702-0	s:	597	 KLVSDLNRLY 606		
	Chimeric, human and humanized anti-CSAP monoclonal antibodies	IMMUNIMEDICS, INC. MORRIS PLAINS, NJ	US7387772-0	Q: s:		RSSQSIVHSNGNTYLQ RSSQSIVHSNGNTYLE	16 39	93.75
	Chimeric, human and humanized anti-CSAp monoclonal antibodies	IMMUNOMEDICS, INC. MORRIS PLAINS, NJ	US7414121-0	Q:	1	Ouory	Results	93.75
6	Production and use of novel peptide-based agents for use	IMMUNOMEDICS, INC. MORRIS PLAINS, NJ	US7429381-0	s:	24	RSS Quely	Nesults	
	with bi-specific antibodies Production and use of novel	IMMUNOMEDICS INC.	US6962702-0	Q:	1	RSSQSIVHSNGNTYLQ	16	93.75
	peptide-based agents for use with bi-specific antibodies	MORRIS PLAINS, NJ		s:	24	RSSQSIVHSNGNTYLE	39	
	Production and use of novel peptide-based agents for use with bi-specific antibodies	IMMUNOMEDICS, INC. MORRIS PLAINS, NJ	US7429381-0	Q: s:	1 24		16 39	93.75
q	Covalently reactive transition state analogs and methods of		US6855804-0	0:	1	RSSQSIVHSNGNTYLO	16	93.75
	use thereof	TEXAS SYSTEM AUSTIN, TX ADLER: BENJAMIN	US7524663-0			1111111111111+	-	55.15
	Covalently reactive transition	ADLER, BENJAWIN	U01024003-L	ລ:	24	RSSQSIVHSNGNTYLE	39	


C	ombined: combined orbit ab a	nd gq three se	eq P					
	Title	Database	FCLA Class	Patent Family			Patent Sequence Location	Percentage Identi
			ACAIC O ATMOTOGACE	Patent	Kind	Date	Location	r or contago idone
3	COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR	FAMPAT	A61K-047/48T2C12P A61K-047/48T4B28 A61K-047/48T4B30 C07K-016/28 C07K-016/28 C07K-016/30 G01N-033/574V4	WO 201166503 CA 2781887 US 20110137016 TW 201124531 WO 201166503 AR 79217 AU 2010324686 IL 219420 EP 2507264	A2 A1 A1 A A3 A1 A1 D0 A2	20110603 20110603 20110609 20110716 20111027 20120104 20120628 20120628 20121010		
4	New isolated antibody comprising complementarity determining region sequence, useful for e.g. treating mammal having cancerous tumor comprising cells (ovarian or lung cancer cells) that express TAT211 polypeptide.	Derwent GeneSeq		WO2011066503		20110603	Claim 34; SEQ ID NO 2; 200pp; English.	88.37
5	New isolated antibody comprising complementarity determining region sequence, useful for e.g. treating mammal having cancerous tumor comprising cells (ovarian or lung cancer cells) that express TAT211 polypeptide.	Derwent GeneSeq		WO2011066503		20110603	Disclosure; SEQ ID NO 1; 200pp; English.	100.00
6	COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR	GQPAT Proteins	C07K16/30 C07K16/28	WO2011066503 AR079217 TW201124531 US20110137016		20110603	claim: 1	88.37
7	COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR	GQPAT Proteins	C07K16/30 C07K16/28	US20110137016 AR079217 TW201124531 WO2011066503		20110609	probable disclosure (not found by automated parsing)	88.37
	COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND	GQPAT Nucleotides	C07K16/30 C07K16/28	US20110137016 AR079217		20110609	probable disclosure (not found by	100.00
























BizInt Smart Charts


Reference Rows[™]

- Information from related records is displayed in a single "Reference Row".
- A separate utility working with patent, drug pipeline, and clinical trial reports.
- Released in December 2011.
- Included in all BizInt Smart Charts licenses.
- Automatically installed in Version 3.5.


BizInt Smart Charts 2013











		Common Family		Summarized Results						
	Title		Datab	Query ID	% Id	entity	Subj S	tart		
16.	Human IGM antibodies with the capability of inducing remyelination , and diagnostic and therapeutic uses thereof particularly in the central nervou s system	EP2287190	16.1 16.2 16.3	Query-A	80.00		27		16,1	
			16.4 16.5 16.6	Query-B Query-A	70.00 80.00		55 27		16.2 16.3	
			16.7 16.8	Query-B Query-A	70.00 80.00		55 27		16.4 16.5	
17.		17. 17. 17. 17. 17. 17. 17.	17.1 17.2	Query-B Query-A	70.00 80.00		55 27		16.6 16.7	
				17.3 17.4 17.5 17.6	Query-B	70.00		55		16.8
			17.8 17.9	GPATPRT link GPATPRT link GPATPRT link GPATPRT link		Query-B Query-A Query-B	82.35 80.00 82.35	50 26 50	1 ¹	
	17.1 GENES		100000000000000000000000000000000000000		17.1 GENES					





































- Visit our Table in the Exhibit
- Cookbook of Reports and Visualizations
- Free Trial and documentation on our website www.bizcharts.com
- Webinars offered monthly

SizInt Smart Charts 2013